ClearPoint Neuro, Inc.
CLPT Healthcare Medical Devices
ClearPoint Neuro, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $37.0 million, up 17.8% from fiscal 2024. In the quarter to June 2026, revenue grew 18.1%, EPS fell 81.0%, free cash flow fell 173.5% and total debt rose 74.1%, each against the same quarter a year earlier. Revenue growth for five consecutive years.
Follow CLPT
ClearPoint Neuro, Inc. (CLPT) EV/Sales
As of 16 October 2026, ClearPoint Neuro, Inc. (CLPT) trades at a EV/Sales of 7.0×. Over the past ten years it has ranged from 1.1× (August 2017) to 35.9× (February 2021); the current reading is higher than 47% of that period. That is above the Medical Devices industry median of 2.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 10.6× | (18.24%) |
| FY2024 | 12.9× | 102.02% |
| FY2023 | 6.4× | (24.31%) |
| FY2022 | 8.5× | (26.91%) |
| FY2021 | 11.6× | (41.40%) |
| FY2020 | 19.7× | 271.11% |
| FY2019 | 5.3× | 100.10% |
| FY2018 | 2.7× | 22.11% |
| FY2017 | 2.2× | (15.29%) |
| FY2016 | 2.6× | (62.17%) |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 13.2× | 89.78% |
| Mar 2026 | 7.0× | (34.04%) |
| Dec 2025 | 10.6× | (40.59%) |
| Sep 2025 | 17.8× | 83.93% |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| LAB Standard BioTools Inc. compare | −2.7× |
| RCEL Avita Medical Inc. compare | 1.3× |
| TMCI Treace Medical Concepts, Inc. compare | 1.3× |
| INFU InfuSystems Holdings, Inc. compare | 2.0× |
| TLSI TriSalus Life Sciences, Inc. compare | 4.4× |
| CLPT ClearPoint Neuro, Inc. | 7.0× |
| CV CapsoVision, Inc. compare | 22.8× |
| CATX Perspective Therapeutics, Inc. compare | 64.7× |
| QSI Quantum-Si Incorporated compare | 82.4× |
| Medical Devices industry median | 2.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)